WASHINGTON A growing push to expand alternative treatments for post-traumatic stress disorder among veterans is drawing mixed reactions, even as the Department of Veterans Affairs explores psychedelic-assisted therapies in formal studies and Congress weighs new legislation. Iraq War veteran Adrian Anthony said the medications he receives through the VA blunt his symptoms but are not a cure, and he remains unconvinced that authorizing psychedelic-assisted treatment would address root causes. He described the continual trade-offs between symptom relief and side effects and said he is skeptical of claims that new modalities will deliver markedly better outcomes. On Capitol Hill, the policy debate has accelerated. Sen. Tommy Tuberville, R-Ala., has introduced a bill centered on alternative mental-health options for veterans, and a related measure passed through the House Veterans Affairs Committee earlier this year. Outside Congress, the VALOR coalitionwhich includes the Green Beret Foundation and Wounded Warrior Projecthas urged lawmakers to permit VA physicians to provide psychedelic-assisted therapies at VA hospitals and clinics, where clinically appropriate, for PTSD, traumatic brain injury, and depression. Supporters frame the effort as expanding options for veterans who have not responded well to standard regimens while keeping care within the VA system and under clinical oversight. Inside the department, research is proceeding with caution. VA press secretary Pete Kasperowicz said the VA currently has 12 clinical studies underway on psychedelic-assisted therapies and emphasized that these approaches would not replace standard mental-health care. That research push overlaps with access constraints that have persisted across the VA network: many hospitals and clinics report staffing shortages tied to nationwide gaps in the supply of physicians and nurses. Anthony, who receives care through the VA, said he has seen multiple psychiatrists at the Savannah clinic and often accepts telephone appointments because those can be scheduled sooner than in-person visits. Workforce dynamics remain a central concern. According to the VA, more than 300 psychiatrists have been hired nationwide since 2023. Even so, some veterans report that appointment delays and provider turnover complicate routine medication management and follow-up. Anthony said such uncertainty adds stress and can undercut confidence in a treatment plan, particularly when symptoms fluctuate or worsen. He also noted that private-sector pay can draw clinicians away from the VA, contributing to changes in providers that disrupt continuity of care. Advocates for expanding access argue that adding psychedelic-assisted therapies is not about displacing established treatments, but about creating a path for veterans who have found limited relief with conventional care. They maintain that access within the VA, guided by clinical protocols, could give some patients a viable alternative while data are gathered. Skeptics, including veterans like Anthony, caution that enthusiasm outpacing evidence could expose vulnerable patients to risk. The debate turns on how quickly the VA should move from controlled studies to clinical use, what guardrails would be required, and how resource constraintsfrom staffing to schedulingmight affect implementation in real clinics. As legislation advances and VA researchers collect results, veterans and families are watching for practical changes. Questions remain about where therapies would be offered, how eligibility would be determined, and how the VAs existing staffing challenges would intersect with any new program. For now, the landscape is defined by measured research, legislative proposals, and a coalition urging expanded authority for VA physicians, set against persistent concerns about access and continuity of care that shape everyday experiences across the system.